Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046613 · ClinicalTrials.gov registry record
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
A clinical trial of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- 780
- Enrollment target
- 1
- Study location
NCT05046613 is a study of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 780 participants, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (122% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05046613, a study of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- 780 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Conditions Studied
Interventions
- OTHER Rimegepant
- OTHER Not taking Rimegepant
Study Locations (1)
North Carolina
- Evidera, a PPD business unit - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2034-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05046613
The ClinicalTrials.gov registry entry for NCT05046613 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 780 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (122% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Rimegepant is the first listed.
NCT05046613 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05046613 about?
NCT05046613 is a clinical study titled "Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant". The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
What is the current status of trial NCT05046613?
This trial is currently recruiting. The enrollment target is 780 participants. The study started on 2021-09-23. Estimated completion is 2034-04-30.
What conditions does trial NCT05046613 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05046613?
The interventions under investigation include: Rimegepant (OTHER), Not taking Rimegepant (OTHER).
Who is sponsoring clinical trial NCT05046613?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05046613 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.